dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Salamero García, Olga |
dc.contributor.author | Willekens, Christophe |
dc.contributor.author | Pérez-Simón, José Antonio |
dc.contributor.author | Pigneux, Arnaud |
dc.contributor.author | Récher, Christian |
dc.contributor.author | Carpio Segura, Cecilia Carmen |
dc.contributor.author | Bosch Albareda, Francesc |
dc.contributor.author | Montesinos, Pau |
dc.date.accessioned | 2021-09-13T12:17:49Z |
dc.date.available | 2021-09-13T12:17:49Z |
dc.date.issued | 2020-12-20 |
dc.identifier.citation | Salamero O, Montesinos P, Willekens C, Pérez-Simón JA, Pigneux A, Récher C, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020 Dec 20;38(36):4260-73. |
dc.identifier.issn | 1527-7755 |
dc.identifier.uri | https://hdl.handle.net/11351/6309 |
dc.description | Leucèmia mieloide aguda; Farmacocinètica; Seguretat |
dc.description.sponsorship | Supported by Oryzon Genomics and IPT-2012-0673-010000 of the INNPACTO program of the Spanish Ministry of Economy and Competitiveness, with contribution of Fondo Europeo de Desarrollo Regional (FEDER) from the European Union and CDTI_CIIP-20131005/ EUROSTAR_E18159. T.C.P.S. is supported by Cancer Research UK Grant No. C5759/A20971. R.P. is supported by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre. |
dc.language.iso | eng |
dc.publisher | American Society of Clinical Oncology |
dc.relation.ispartofseries | Journal of Clinical Oncology;38(36) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia mieloide aguda |
dc.subject | Inhibidors enzimàtics - Ús terapèutic |
dc.subject.mesh | Leukemia, Myeloid, Acute |
dc.subject.mesh | Enzyme Inhibitors |
dc.subject.mesh | /therapeutic use |
dc.title | First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1200/JCO.19.03250 |
dc.subject.decs | leucemia mieloide aguda |
dc.subject.decs | inhibidores enzimáticos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1200/JCO.19.03250 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Salamero O, Carpio C, Bosch F] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Montesinos P] Hospital Universitari I Politécnic La Fe, València, Spain. Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain. [Willekens C] Institut Gustave Roussy, Villejuif Cedex, France. [Pérez-Simón JA] Hospital Universitario Virgen del Rocío, Sevilla, Spain. Instituto de Biomedicina de Sevilla (Insitituto de Biomedicina De Sevilla/Consejo Superior De Investigaciones Científicas/Centro de Investigación Biomédica en Red de Cáncer), Universidad de Sevilla, Sevilla, Spain. [Pigneux A] Centre Hospitalier Universitaire CHU Bordeaux, Hôpital du Haut Lévêque, Pessac, France. [Récher C] Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France |
dc.identifier.pmid | 33052756 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/1PN/IPT-2012-0673-010000 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |